Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

Artificial intelligence and machine learning (ML) promise to transform cancer therapies by
accurately predicting the most appropriate therapies to treat individual patients. Here, we …

Cancer is a complex disease displaying a variety of cell states and phenotypes. This
diversity, known as cancer cell plasticity, confers cancer cells the ability to change in …

Mass spectrometry-based omics technologies are increasingly used in perturbation studies
to map drug effects to biological pathways by identifying significant molecular events …

Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK
signaling is only beneficial to a small subset of patients due to resistance that arises through …

Melanoma cells are notorious for their high plasticity and ability to switch back and forth
between various melanoma cell states, enabling the adaptation to sub-optimal conditions …

Purpose: Despite high clinical need, there are no biomarkers that accurately predict the
response of patients with metastatic melanoma to anti-PD-1 therapy. Experimental Design …

Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted
therapy treatments, such as MAPK inhibitors (MAPKi). A leading cause of resistance to …

Background: Despite recent improvements in therapy, the five-year survival rate for patients
with advanced melanoma is poor, mainly due to the development of drug resistance. The …